Related Experiment Videos

Myelography wiht perfluoroctylbromide. Comparison with Pantopaque

Insights

Perfluoroctylbromide is a promising, low-toxicity contrast agent for myelography, offering good radiopacity for subarachnoid imaging in dogs. Further study may be needed regarding its long retention in the intrathecal space.

Area of Science:

  • Radiology
  • Toxicology
  • Veterinary Medicine

Background:

  • Myelography requires effective and safe contrast media for diagnosing subarachnoid space abnormalities.
  • Current contrast agents like Pantopaque may cause irritation and have limitations.

Purpose of the Study:

  • To evaluate the efficacy and toxicity of perfluoroctylbromide as a contrast medium for intrathecal use in dogs.

Main Methods:

  • Dogs were administered varying doses of perfluoroctylbromide intrathecally.
  • Efficacy was assessed by radiopacity and diagnostic quality.
  • Toxicity was evaluated through clinical signs, histological studies, and cerebrospinal fluid (CSF) analysis.

Main Results:

  • Perfluoroctylbromide demonstrated free movement within the intrathecal space and provided satisfactory radiopacity.
  • Dogs tolerated doses of 0.5-1.0 ml/kg without observable toxic manifestations.
  • Histological findings and CSF analyses indicated significantly less irritation compared to Pantopaque.

Conclusions:

  • Perfluoroctylbromide exhibits a favorable safety profile and diagnostic utility for myelography in canine models.
  • Its low toxicity and good radiopacity make it a promising alternative contrast agent.
  • Consideration for perfluorocarbon removal may be necessary due to its long retention time.

Related Concept Videos